Innovative Diagnostic Technologies Cisbio specializes in proprietary HTRF fluorescence detection technology and offers a broad range of immunoassays for in vitro diagnostics, particularly targeting cancerous, metabolic, and autoimmune diseases, presenting opportunities for collaboration on advanced medical diagnostic products.

Global Market Presence With facilities in France, the U.S., Japan, and China, and a worldwide market reach, Cisbio is positioned to deploy new diagnostic assays and expand its global customer base across multiple regions and healthcare markets.

Growing Revenue Range Generating between $10 million and $25 million, Cisbio demonstrates solid market traction, making it a promising candidate for strategic partnerships or technology licensing to accelerate growth and innovation.

Parent Company Leverage As part of PerkinElmer, Cisbio can leverage corporate resources, R&D capabilities, and distribution channels, providing sale teams with opportunities to pitch complementary or enhanced solutions to existing clients.

Technological and Scientific Edge Cisbio's focus on homogeneous fluorescence detection and bioassay development positions it well to adopt and integrate emerging biotech technologies, offering potential for joint innovation and co-development initiatives.